What Do Clinical Trials Show About Stem Cell Injections for Knee Osteoarthritis?
Published November 16, 2026
Protocol: 7 steps in this guide
Randomized trials of cell injections for knee osteoarthritis show modest improvements in some pain and function scores, mixed results on others, and no consistent improvement in joint structure on MRI. They also show more local reactions, such as injection-site pain and swelling, than control injections. A 2026 meta-analysis of 28 randomized trials concluded that these therapies serve “a primarily symptom-modifying rather than structure-modifying role.” The U.S. Department of Veterans Affairs and Department of Defense guideline, based on evidence through July 2025, found insufficient evidence to recommend for or against stem cell injections for knee osteoarthritis. No cell product is FDA-approved for it.
Which preparations are being tested
“Stem cell injection” covers very different products, and results for one do not transfer to another:
- Culture-expanded MSCs: stromal cells isolated and grown in a laboratory, from the patient or a donor.
- Bone marrow aspirate concentrate (BMAC): a same-day concentrate of marrow cells, covered in what bone marrow aspirate concentrate is.
- Adipose-derived preparations: stromal vascular fraction or fat-derived cells, covered in what stromal vascular fraction from adipose tissue is.
The 2026 meta-analysis, by Awad and colleagues in Clinical Rheumatology, noted that trials “report inconsistent results due to heterogeneity in cell sources, preparations, and techniques,” and found that benefits “were more consistent with culture-expanded preparations, bone marrow sources, saline controls, and ultrasound guidance.”
Placebo and active comparators
The comparator decides what a result means. The table summarizes the main recent evidence by comparison.
| Source | Products | Comparator | Symptom result | Structure result | Notes |
|---|---|---|---|---|---|
| Awad and colleagues, meta-analysis (2026); 28 RCTs | MSC-based therapies | Various controls | Improved VAS pain and some KOOS domains; no significant difference in WOMAC, KOOS quality of life or Lequesne | MRI WORMS not significant | More injection-site pain and swelling |
| VA/DoD review of Whittle and colleagues (2025) | Stem cells | Placebo, 7 RCTs | Better function up to 6 months; no difference at later time points | Not the focus | Very serious limitations noted |
| Garza and colleagues, American Journal of Sports Medicine (2026); 114 randomized | Autologous SVF, 25 million cells, one injection | Placebo | 12-month responder rate 51.8% vs 29% (one-sided P = .0149) | MRI obtained; abstract reports no structural result | Device study sponsored by GID BIO, INC |
The VA/DoD guideline also reports, from the same review, that “autologous stem cells improve function better than placebo, but there is no difference between allogenic stem cells versus placebo,” and that evidence from four trials in a 2024 review of BMAC “was unable to find differences between BMAC and other treatments for improving function.”
Pain and function versus cartilage
In the 2026 meta-analysis, the significant gains were in symptom scores. It reported that “MRI-based WORMS scores were non-significant, indicating no consistent structural benefit.” Whether any cell product rebuilds cartilage is the subject of whether stem cell products can regrow damaged joint cartilage in humans. Score thresholds and what counts as a meaningful change are covered in what clinically meaningful improvement means in a joint pain study.
Adverse events and follow-up
The 2026 meta-analysis found higher rates of injection-site pain (risk ratio 2.04), joint swelling (risk ratio 3.39) and other adverse events (risk ratio 1.26) with stem cell therapies, while serious complications such as infection were, in its words, “uncommon and non-significant.” The Garza SVF trial reported no serious investigational device-related adverse events at 12 months. SVF also requires liposuction, which adds its own procedure. The abstracts used here do not give every trial’s follow-up, and the Garza trial reported results at 12 months, which limits what this article can say about long-term effects; how longer-term safety is tracked is covered in how researchers monitor long-term safety after cell therapy.
The VA/DoD 2026 position
The VA/DoD Clinical Practice Guideline for the Non-Surgical Management of Hip & Knee Osteoarthritis (May 2026) states: “For osteoarthritis of the knee, there is insufficient evidence to recommend for or against” several injections, including stem cell injections, for which it gives mesenchymal, adipose-derived and bone marrow-derived cells as examples. Its discussion notes that these preparations “are believed to exert their proposed effects primarily through paracrine signaling, immunomodulation, and modulation of the local inflammatory environment rather than through direct tissue engraftment or durable structural regeneration.” The guideline states that it is based on evidence reviewed through July 31, 2025, so it predates both the 2026 meta-analysis and the Garza trial. “Insufficient evidence” means uncertainty, not proof that the injections do nothing.
How to read small and sponsored trials
Several features of this evidence call for caution:
- Small samples. Small trials can produce large effects by chance, so single small positive results need confirmation.
- Comparator choice. A saline placebo, a numbing injection, hyaluronic acid and no treatment answer different questions; the meta-analysis found more consistent benefits against saline.
- Uneven groups. The Garza trial randomized 83 people to SVF and 31 to placebo, so the placebo group was small.
- Sponsorship. CMS’s record for IDE study BB16734-NCT04440189 lists the trial as a pivotal study of the “GID SVF-2 Device” sponsored by GID BIO, INC. Sponsorship does not make a result wrong, but it is a reason to read the full methods.
- Responder endpoints. A composite “responder” rate depends on how the threshold was defined in advance; it should be read alongside the actual score changes.
Why placebo control matters is explained in the difference between a placebo-controlled trial and an observational study.
What remains unapproved
FDA’s patient and consumer information on regenerative medicine therapies states that the unapproved regenerative products it warns about “have not been approved for the treatment of any orthopedic condition, such as osteoarthritis.” The one FDA-approved stromal cell product, Ryoncil, is approved for a pediatric transplant complication, not for joints. An SVF trial under an investigational device exemption is research, not approval. How the rules apply is covered in how the FDA regulates stem cell products promoted for joint pain, and the comparable PRP evidence in what the evidence says about PRP for knee osteoarthritis.
Randomized trials suggest that some cell injections modestly improve knee osteoarthritis symptoms for a period, with more local reactions and no consistent structural benefit, and with products varying widely and none FDA-approved for the knee, the evidence supports cautious, product-specific research rather than routine use.
Cells linked to this one
This guide leads on to
- E3 What Is Bone Marrow Aspirate Concentrate (BMAC)?
- E4 What Is Stromal Vascular Fraction (SVF) From Adipose Tissue?
- F3 Can Stem Cell Products Regrow Damaged Joint Cartilage in Humans?
- I9 What Does Clinically Meaningful Improvement Mean in a Joint Pain Study?
- I6 How Do Researchers Monitor Long-Term Safety After Cell Therapy?
- I8 What Is the Difference Between a Placebo-Controlled Trial and an Observational Study?
- F11 How Does the FDA Regulate Stem Cell Products Promoted for Joint Pain?
- C1 What Does the Evidence Say About PRP for Knee Osteoarthritis?
Guides that lead here
- A7 What Is the Extracellular Matrix, and Why Does It Matter for Healing?
- I10 Why Can Pain Scores Improve Without Cartilage Regrowth on MRI?
- I5 Why Do Stem Cell Injection Prices Vary So Widely?
- E9 What Does Cell Viability Mean for Injectable Cell Products?
- F8 What Is the Clinical Evidence for Cell-Based Therapy in Rheumatoid Arthritis?
- H7 BMAC vs. Autologous Chondrocyte Implantation for Focal Knee Cartilage Defects: What Is the Difference?
- E6 What Is Wharton's Jelly, and Why Is It Marketed for Joint Injections?
Add a remark